Autopsy report · NCT02833506
Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Cause of deathFunding or business, also drug or device supply
“production of adjuvant to be used with vaccine was discontinued by sponsor”
Life of this trial
- Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.
Vital statistics
- Status
- Withdrawn
- Phase
- Phase 1
- Sponsor
- Roswell Park Cancer Institute
- Sponsor type
- University, hospital or other
- Conditions
- Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Cancer; Stage IIB Fallopian Tube Cancer
- Interventions
- Laboratory Biomarker Analysis; Recombinant NY-ESO-1 Protein; Sirolimus
- Participants
- 0
- Sites
- 1
- Countries
- United States
Trials that died the same way
- Personalized Tumor Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma
“Vaccine manufacturing has been suspended”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.